ProKidney Corp
PROK1.870USD
+0.140+8.09%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
254.28MCap. mercado
PérdidaP/E TTM
Más Datos de ProKidney Corp Compañía
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Información de ProKidney Corp
Símbolo de cotizaciónPROK
Nombre de la empresaProkidney Corp
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoCulleton (Bruce)
Número de empleados204
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 30
Dirección2000 Frontis Plaza Blvd
CiudadWINSTON-SALEM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27103
Teléfono13369997028
Sitio Webhttps://prokidney.com/
Símbolo de cotizaciónPROK
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoCulleton (Bruce)
Ejecutivos de ProKidney Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
+1537020.00%
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Alan M. Lotvin, M.D.
Dr. Alan M. Lotvin, M.D.
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Mr. Jose Ignacio Jimenez Santos
Mr. Jose Ignacio Jimenez Santos
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
+1537020.00%
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
Otro
60.77%
Accionistas
Accionistas
Proporción
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
Otro
60.77%
Tipos de accionistas
Accionistas
Proporción
Corporation
23.56%
Hedge Fund
11.04%
Investment Advisor
10.26%
Investment Advisor/Hedge Fund
6.12%
Individual Investor
1.83%
Research Firm
0.90%
Endowment Fund
0.71%
Bank and Trust
0.04%
Family Office
0.02%
Otro
45.52%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
178
41.07M
29.01%
-2.81M
2025Q3
180
38.60M
28.59%
-15.99M
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Tolerantia LLC
22.62M
15.98%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
8.72%
--
--
Sep 30, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
7.58%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
6.41M
4.53%
+698.99K
+12.24%
Sep 30, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.42%
--
--
Oct 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.73%
--
--
Nov 30, 2025
Bleichroeder LP
2.00M
1.41%
--
--
Sep 30, 2025
Millennium Management LLC
1.96M
1.38%
+1.96M
--
Sep 30, 2025
The Vanguard Group, Inc.
1.56M
1.1%
-3.75K
-0.24%
Sep 30, 2025
Culleton (Bruce)
1.54M
1.09%
+1.54M
--
Mar 17, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Schwab U.S. Small-Cap ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Ver más
Schwab U.S. Small-Cap ETF
Proporción0.01%
ALPS Medical Breakthroughs ETF
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
Schwab U.S. Broad Market ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Avantis US Equity ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
